ImmunityBio (NASDAQ:IBRX) Director Sells $187,750.00 in Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 25,000 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christobel Selecky also recently made the following trade(s):

• On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00.

ImmunityBio Stock Up 6.8%

Shares of IBRX stock traded up $0.44 on Wednesday, hitting $6.92. The company had a trading volume of 95,661,091 shares, compared to its average volume of 33,482,678. The firm has a market cap of $6.82 billion, a P/E ratio of -16.88 and a beta of 0.03. The company has a 50-day moving average price of $2.54 and a 200-day moving average price of $2.52. ImmunityBio, Inc. has a twelve month low of $1.83 and a twelve month high of $7.98.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to analyst estimates of $31.88 million. Equities research analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Piper Sandler increased their price objective on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a report on Tuesday. Finally, Jefferies Financial Group boosted their price target on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, ImmunityBio currently has an average rating of “Moderate Buy” and an average price target of $12.00.

Institutional Trading of ImmunityBio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its position in ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after acquiring an additional 29,297 shares during the last quarter. Rhumbline Advisers grew its position in shares of ImmunityBio by 5.6% during the 1st quarter. Rhumbline Advisers now owns 219,360 shares of the company’s stock worth $660,000 after buying an additional 11,573 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of ImmunityBio during the 2nd quarter worth about $43,000. Wealth Effects LLC raised its position in shares of ImmunityBio by 23.9% during the second quarter. Wealth Effects LLC now owns 122,000 shares of the company’s stock worth $322,000 after purchasing an additional 23,500 shares during the period. Finally, Plancorp LLC bought a new stake in ImmunityBio during the 2nd quarter worth approximately $717,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.